Pancreatitis%20-%20chronic Treatment

Treatment

Surgical Intervention

Early surgical intervention may more effectively relieve pain, decrease the need for re-intervention and improve pancreatic function preservation
Surgery may be considered in the following groups of patients:
- With persistent pain unresponsive to medical therapy
- Patients whose pancreatic ductal anatomy is not suitable for endoscopic treatment
- Patients in whom endoscopic therapy has failed
  - Surgery is superior to endoscopy for control of pain in a dilated pancreatic duct
- Presence of complications, eg infection or symptomatic compression of adjacent structures
- As 1st-line treatment for suspected pancreatic cancer
Procedures that may be performed are pseudocyst decompression, ductal decompression, pancreatic resection, denervation procedures, and total pancreatectomy
The choice of procedure depends on the patient’s predominant condition, though more preferred are the tissue-preserving procedures
- Ductal dilatation is best treated with drainage and decompression procedures
- “Small-duct” disease is usually treated with pancreatic resection
- Pseudocysts >5 cm in size and persisting for >6 months should be drained
- Refractory chronic pain in highly selected patients is treated with total pancreatectomy with islet autotransplant only when all other treatment measures are unsuccessful

Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma

Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).

Product Highlight - Salofalk

12 Mar 2021

SALOFALK – Mesalazine 1.5 g PR granules

Long COVID: What we have learned so far

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.